Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

AIMS: Vatalanib is an oral anti-angiogenesis agent that inhibits vascular endothelial growth factor receptor tyrosine kinases, which in patients showed auto induction of metabolism and variability in pharmacokinetic (PK) disposition. The objective was to characterize the population PK and time-depen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Wang, Xiaofeng, Owzar, Kouros, Gupta, Pankaj, Larson, Richard A, Mulkey, Flora, Miller, Antonius A, Lewis, Lionel D, Hurd, David, Vij, Ravi, Ratain, Mark J, Murry, Daryl J
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4243874/
https://ncbi.nlm.nih.gov/pubmed/24838014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12427
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados